Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:22:40.977Z.
Calculation as of: 2026-10-06T18:22:40.977Z.
Quote observation: 2026-10-06T18:19:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e64ee45e162b8fcb3c04564696a4f5631675aa9d571ebc51c9b2157b48bafcf8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Rani Therapeutics Holdings, Inc.
Market Cap
$52.95M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.46M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.16M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$54.50M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $52.95M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $52.73M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.24M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.16M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.83M | 2.13 | 2.08 | 4.49 | 3.97 |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $54.50M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
